BPC-157 Canada: Research, Testing and Regulatory Information
BPC-157 is a synthetic research peptide primarily examined in preclinical laboratory models.
This overview explains its research status, Canadian regulatory context, analytical
documentation and the standards that qualified laboratories should consider when evaluating
BPC-157 research material.
represented as an authorized drug, treatment, supplement, cosmetic product, or product for
human or animal consumption.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids. Published research
has investigated the compound in experimental models involving several biological
processes. Much of the available literature remains preclinical, including animal and
laboratory studies.
Findings from preclinical experiments cannot establish safety, effectiveness, or an
appropriate application in humans. Limited human observations do not replace
appropriately designed, controlled clinical trials.
Current research status
BPC-157 remains an experimental compound. It should not be described as clinically proven,
approved, safe, or effective for treating a medical condition.
Qualified researchers should distinguish proposed biological mechanisms from established
clinical evidence and should review the methodology, sample size, model, controls and
limitations of each publication before interpreting its findings.
BPC-157 and Canadian regulatory status
BPC-157 is not an authorized therapeutic product in Canada. It does not have a Health Canada
Drug Identification Number for therapeutic sale. Health Canada has also identified BPC-157
in public advisories concerning unauthorized injectable peptide drugs marketed for human use.
A “research use only” label does not authorize a product to be marketed as a drug or exempt
a seller from Canadian regulatory requirements. Product presentation, claims, intended use
and surrounding circumstances all matter. PeptidePro Canada therefore does not provide
therapeutic claims, personal-use recommendations, dosing, administration, reconstitution,
or treatment guidance.
Institutions are responsible for determining whether their proposed acquisition, possession
and research activity comply with applicable federal, provincial and institutional
requirements. This page is general product information and is not legal or regulatory advice.
Understanding BPC-157 laboratory documentation
A Certificate of Analysis should identify the tested batch and report the analytical results
produced for that sample. A purity percentage alone does not confirm every aspect of material
quality. Identity, measured content and contaminant testing address different questions and
should be considered separately.
| Analytical check | What it evaluates | Why it matters |
|---|---|---|
| Identity | Whether the detected compound is consistent with the expected molecular identity. | Helps distinguish the intended compound from an incorrect or substituted material. |
| Purity |
The relative proportion of the principal peptide signal compared with detected impurities. |
Purity does not, by itself, establish the total amount contained in a vial. |
| Mass or content | The measured amount of peptide material associated with the tested sample. | Provides information separate from chromatographic purity. |
| Heavy metals | Selected elemental contaminants included within the laboratory panel. | Documents whether tested metals were detected within the method’s reporting limits. |
| Endotoxin and sterility | Microbiological characteristics of the samples tested by the laboratory. |
Results are batch- and sample-specific and do not convert a research reagent into an authorized drug. |
Dual-lab batch verification
PeptidePro Canada uses two independent laboratories to document current research batches.
Janoshik Analytical and Kovera Labs perform different, complementary analytical work rather
than relying on one purity result or an unverified supplier document.
- Independent identity, purity and measured-content documentation
- Multi-vial conformity testing within the applicable Kovera panel
- Heavy-metal, endotoxin and sterility testing where listed on the posted reports
- Batch identifiers connecting the vial label with its corresponding documentation
- Current reports displayed with the product rather than a generic example certificate
Laboratory findings apply only to the samples and batch identified in the reports. They
should not be interpreted as approval by Health Canada or as evidence of clinical safety or
effectiveness.
Storage of unopened lyophilized material
Dry-form storage only: Keep the unopened lyophilized research material
refrigerated at 2–8°C, protected from light and moisture, unless the batch documentation
specifies otherwise.
Minimize unnecessary temperature cycling and keep the vial sealed until required under an
approved laboratory procedure. Laboratories should document receipt, storage conditions,
batch identity and chain of custody under their own SOPs.
This storage information applies only to the sealed, dry research material. PeptidePro
Canada does not provide reconstitution, dilution, administration, dosing, or personal-use
instructions.
Available BPC-157 Canada Format
The current BPC-157 research format is supplied as 10mg of lyophilized material in a
3 mL glass vial. Orders ship from Ontario, Canada, and current availability is shown on
the product page.
BPC-157 Canada 10mg
Lyophilized BPC-157 research material supplied for controlled, non-clinical laboratory
work by qualified facilities and trained personnel.
For laboratory research use only. Not for human or animal consumption, clinical,
therapeutic, diagnostic, cosmetic, or personal use.
Current-batch documentation
Review the batch identifiers and independent laboratory reports displayed with the
current product. Posted results apply only to the samples and batch identified on the
corresponding documentation.
WADA status
BPC-157 is included in the World Anti-Doping Agency Prohibited List under the category of
non-approved substances. The 2026 Prohibited List is effective from January 1, 2026.
Researchers, testing facilities and sport organizations should consult the current official
list rather than relying on older summaries.
BPC-157 Canada FAQ
Is BPC-157 approved by Health Canada?
No. BPC-157 is not an authorized therapeutic product in Canada. PeptidePro Canada supplies
it only as a non-clinical laboratory research reagent and does not represent it as a drug,
treatment, supplement, or product for personal use.
Does BPC-157 have established human clinical evidence?
The published evidence is dominated by preclinical research. Limited human reports do not
establish clinical safety or effectiveness. Claims based on animal or laboratory findings
should not be presented as proven human outcomes.
What does “research use only” mean?
It means the material is offered for controlled, non-clinical laboratory work by qualified
facilities and trained personnel. It is not intended for human or animal consumption,
clinical treatment, diagnosis, cosmetic use, or personal experimentation.
Where can the current BPC-157 COAs be reviewed?
Current batch documentation is displayed with the BPC-157 10mg product. The vial’s batch
identifier should be compared with the identifiers shown on the corresponding laboratory
reports.
Does a high purity result confirm the amount in the vial?
No. Purity and measured content are different analytical measurements. This is why a useful
batch review considers identity, purity and measured content separately, together with any
additional testing reported for that batch.
Review the Current BPC-157 Research Batch
View the 10mg research format, current availability and corresponding independent batch
documentation.
Official and scientific references
Regulatory information:
Health Canada peptide advisory
Sport regulation:
World Anti-Doping Agency Prohibited List
Research literature:
PubMed-indexed BPC-157 narrative review